RT Journal Article
SR Electronic
T1 Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e002057
DO 10.1136/jitc-2020-002057
VO 9
IS 6
A1 Zakharia, Yousef
A1 McWilliams, Robert R
A1 Rixe, Olivier
A1 Drabick, Joseph
A1 Shaheen, Montaser F
A1 Grossmann, Kenneth F
A1 Kolhe, Ravindra
A1 Pacholczyk, Rafal
A1 Sadek, Ramses
A1 Tennant, Lucinda L
A1 Smith, Christopher M
A1 Kennedy, Eugene P
A1 Link Jr, Charles J
A1 Vahanian, Nicholas N
A1 Yu, Jiayi
A1 Shen, Steven S
A1 Brincks, Erik L
A1 Rossi, Gabriela R
A1 Munn, David
A1 Milhem, Mohammed
YR 2021
UL http://jitc.bmj.com/content/9/6/e002057.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.